CN106913627A - A kind of blue anti-inflammatory syrup in children Pu ground and preparation method thereof - Google Patents
A kind of blue anti-inflammatory syrup in children Pu ground and preparation method thereof Download PDFInfo
- Publication number
- CN106913627A CN106913627A CN201710164692.7A CN201710164692A CN106913627A CN 106913627 A CN106913627 A CN 106913627A CN 201710164692 A CN201710164692 A CN 201710164692A CN 106913627 A CN106913627 A CN 106913627A
- Authority
- CN
- China
- Prior art keywords
- ground
- blue
- extract
- syrup
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000006188 syrup Substances 0.000 title claims abstract description 71
- 235000020357 syrup Nutrition 0.000 title claims abstract description 71
- 230000003110 anti-inflammatory effect Effects 0.000 title claims abstract description 34
- 238000002360 preparation method Methods 0.000 title claims abstract description 26
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 66
- 239000000284 extract Substances 0.000 claims abstract description 36
- 238000001556 precipitation Methods 0.000 claims abstract description 35
- 239000003814 drug Substances 0.000 claims abstract description 33
- 238000000034 method Methods 0.000 claims abstract description 33
- 238000003809 water extraction Methods 0.000 claims abstract description 26
- 241000050051 Chelone glabra Species 0.000 claims abstract description 19
- 201000007100 Pharyngitis Diseases 0.000 claims abstract description 17
- 240000001949 Taraxacum officinale Species 0.000 claims abstract description 16
- 235000005187 Taraxacum officinale ssp. officinale Nutrition 0.000 claims abstract description 16
- 239000010231 banlangen Substances 0.000 claims abstract description 16
- 239000002994 raw material Substances 0.000 claims abstract description 4
- 235000015360 Taraxacum officinale ssp. ceratophorum Nutrition 0.000 claims abstract description 3
- 235000019441 ethanol Nutrition 0.000 claims description 43
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 33
- 239000000686 essence Substances 0.000 claims description 27
- 229930006000 Sucrose Natural products 0.000 claims description 22
- 239000005720 sucrose Substances 0.000 claims description 22
- 229940079593 drug Drugs 0.000 claims description 19
- 235000003599 food sweetener Nutrition 0.000 claims description 14
- 235000019408 sucralose Nutrition 0.000 claims description 14
- 239000003765 sweetening agent Substances 0.000 claims description 14
- 239000004376 Sucralose Substances 0.000 claims description 13
- 235000019202 steviosides Nutrition 0.000 claims description 13
- BAQAVOSOZGMPRM-QBMZZYIRSA-N sucralose Chemical compound O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@@]1(CCl)[C@@H](O)[C@H](O)[C@@H](CCl)O1 BAQAVOSOZGMPRM-QBMZZYIRSA-N 0.000 claims description 13
- 239000004383 Steviol glycoside Substances 0.000 claims description 12
- 235000019411 steviol glycoside Nutrition 0.000 claims description 12
- 229930182488 steviol glycoside Natural products 0.000 claims description 12
- 150000008144 steviol glycosides Chemical class 0.000 claims description 12
- 206010061218 Inflammation Diseases 0.000 claims description 10
- 239000006286 aqueous extract Substances 0.000 claims description 10
- 238000000605 extraction Methods 0.000 claims description 10
- 238000001914 filtration Methods 0.000 claims description 10
- 239000007788 liquid Substances 0.000 claims description 10
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 9
- 208000005647 Mumps Diseases 0.000 claims description 7
- 208000010805 mumps infectious disease Diseases 0.000 claims description 7
- 239000006228 supernatant Substances 0.000 claims description 6
- 239000000706 filtrate Substances 0.000 claims description 5
- 239000000463 material Substances 0.000 claims description 5
- 239000006071 cream Substances 0.000 claims description 4
- 230000004054 inflammatory process Effects 0.000 claims description 4
- 230000001154 acute effect Effects 0.000 claims description 3
- 229930182470 glycoside Natural products 0.000 claims description 3
- 150000002338 glycosides Chemical class 0.000 claims description 3
- 235000009508 confectionery Nutrition 0.000 claims description 2
- 239000002904 solvent Substances 0.000 claims description 2
- 125000000185 sucrose group Chemical group 0.000 claims description 2
- 240000000111 Saccharum officinarum Species 0.000 claims 2
- 235000007201 Saccharum officinarum Nutrition 0.000 claims 2
- 244000144730 Amygdalus persica Species 0.000 claims 1
- 235000006040 Prunus persica var persica Nutrition 0.000 claims 1
- 239000002304 perfume Substances 0.000 claims 1
- 235000000346 sugar Nutrition 0.000 claims 1
- 230000008569 process Effects 0.000 abstract description 14
- 238000004519 manufacturing process Methods 0.000 abstract description 10
- 201000010099 disease Diseases 0.000 abstract description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 6
- 230000000694 effects Effects 0.000 abstract description 6
- 235000019640 taste Nutrition 0.000 abstract description 6
- 206010044008 tonsillitis Diseases 0.000 abstract description 4
- 230000009286 beneficial effect Effects 0.000 abstract description 3
- 239000000825 pharmaceutical preparation Substances 0.000 abstract description 3
- 206010034038 Parotitis Diseases 0.000 abstract description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 30
- 206010011224 Cough Diseases 0.000 description 29
- 238000012360 testing method Methods 0.000 description 28
- 241000700159 Rattus Species 0.000 description 22
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 20
- 238000002474 experimental method Methods 0.000 description 18
- XDQITMCFPPPMBC-TUANDBMESA-N scutelloside Natural products OC[C@H]1O[C@@H](O[C@@H]2O[C@@H]3C[C@H]4[C@H](O)[C@@H](O)[C@@](O)(CO3)[C@@H]24)[C@H](O)[C@@H](O)[C@@H]1O XDQITMCFPPPMBC-TUANDBMESA-N 0.000 description 17
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 15
- 230000037396 body weight Effects 0.000 description 11
- YDDGKXBLOXEEMN-UHFFFAOYSA-N Di-E-caffeoyl-meso-tartaric acid Natural products C=1C=C(O)C(O)=CC=1C=CC(=O)OC(C(O)=O)C(C(=O)O)OC(=O)C=CC1=CC=C(O)C(O)=C1 YDDGKXBLOXEEMN-UHFFFAOYSA-N 0.000 description 10
- 235000011114 ammonium hydroxide Nutrition 0.000 description 10
- YDDGKXBLOXEEMN-IABMMNSOSA-N chicoric acid Chemical compound O([C@@H](C(=O)O)[C@@H](OC(=O)\C=C\C=1C=C(O)C(O)=CC=1)C(O)=O)C(=O)\C=C\C1=CC=C(O)C(O)=C1 YDDGKXBLOXEEMN-IABMMNSOSA-N 0.000 description 10
- 229930016920 cichoric acid Natural products 0.000 description 10
- 235000006193 cichoric acid Nutrition 0.000 description 10
- YDDGKXBLOXEEMN-WOJBJXKFSA-N dicaffeoyl-L-tartaric acid Natural products O([C@@H](C(=O)O)[C@@H](OC(=O)C=CC=1C=C(O)C(O)=CC=1)C(O)=O)C(=O)C=CC1=CC=C(O)C(O)=C1 YDDGKXBLOXEEMN-WOJBJXKFSA-N 0.000 description 10
- 244000298479 Cichorium intybus Species 0.000 description 9
- 235000007542 Cichorium intybus Nutrition 0.000 description 9
- AKJDEXBCRLOVTH-UHFFFAOYSA-N Carbetapentane citrate Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.C=1C=CC=CC=1C1(C(=O)OCCOCCN(CC)CC)CCCC1 AKJDEXBCRLOVTH-UHFFFAOYSA-N 0.000 description 8
- URLKBWYHVLBVBO-UHFFFAOYSA-N Para-Xylene Chemical group CC1=CC=C(C)C=C1 URLKBWYHVLBVBO-UHFFFAOYSA-N 0.000 description 8
- 239000002253 acid Substances 0.000 description 8
- 238000000540 analysis of variance Methods 0.000 description 8
- 239000000203 mixture Substances 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- 241000700199 Cavia porcellus Species 0.000 description 6
- 241001062009 Indigofera Species 0.000 description 6
- 230000000954 anitussive effect Effects 0.000 description 6
- 239000007921 spray Substances 0.000 description 6
- 102000004889 Interleukin-6 Human genes 0.000 description 5
- 108090001005 Interleukin-6 Proteins 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 5
- 208000016150 acute pharyngitis Diseases 0.000 description 5
- 206010001093 acute tonsillitis Diseases 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 238000010171 animal model Methods 0.000 description 5
- 230000004856 capillary permeability Effects 0.000 description 5
- 238000003304 gavage Methods 0.000 description 5
- 210000003800 pharynx Anatomy 0.000 description 5
- 238000004321 preservation Methods 0.000 description 5
- 241000894007 species Species 0.000 description 5
- 230000001954 sterilising effect Effects 0.000 description 5
- 235000019605 sweet taste sensations Nutrition 0.000 description 5
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 230000033228 biological regulation Effects 0.000 description 4
- 238000004140 cleaning Methods 0.000 description 4
- 238000013461 design Methods 0.000 description 4
- 230000014509 gene expression Effects 0.000 description 4
- 239000008187 granular material Substances 0.000 description 4
- 238000005286 illumination Methods 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 238000007689 inspection Methods 0.000 description 4
- 238000011835 investigation Methods 0.000 description 4
- 230000000384 rearing effect Effects 0.000 description 4
- 206010014025 Ear swelling Diseases 0.000 description 3
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 3
- IPQKDIRUZHOIOM-UHFFFAOYSA-N Oroxin A Natural products OC1C(O)C(O)C(CO)OC1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC=CC=1)O2 IPQKDIRUZHOIOM-UHFFFAOYSA-N 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- IKIIZLYTISPENI-ZFORQUDYSA-N baicalin Chemical compound O1[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC=CC=1)O2 IKIIZLYTISPENI-ZFORQUDYSA-N 0.000 description 3
- 229960003321 baicalin Drugs 0.000 description 3
- AQHDANHUMGXSJZ-UHFFFAOYSA-N baicalin Natural products OC1C(O)C(C(O)CO)OC1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC=CC=1)O2 AQHDANHUMGXSJZ-UHFFFAOYSA-N 0.000 description 3
- 230000003115 biocidal effect Effects 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 229940098391 carbetapentane citrate Drugs 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 230000000052 comparative effect Effects 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 235000012907 honey Nutrition 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 210000004493 neutrocyte Anatomy 0.000 description 3
- 230000001575 pathological effect Effects 0.000 description 3
- 229960003436 pentoxyverine Drugs 0.000 description 3
- 238000005057 refrigeration Methods 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 238000013112 stability test Methods 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- 230000008961 swelling Effects 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 208000035473 Communicable disease Diseases 0.000 description 2
- 102000003712 Complement factor B Human genes 0.000 description 2
- 108090000056 Complement factor B Proteins 0.000 description 2
- 240000001624 Espostoa lanata Species 0.000 description 2
- 235000009161 Espostoa lanata Nutrition 0.000 description 2
- 240000001307 Myosotis scorpioides Species 0.000 description 2
- 206010068319 Oropharyngeal pain Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 210000000683 abdominal cavity Anatomy 0.000 description 2
- 229960001138 acetylsalicylic acid Drugs 0.000 description 2
- -1 and for orally using Substances 0.000 description 2
- 125000003118 aryl group Chemical group 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000004925 denaturation Methods 0.000 description 2
- 230000036425 denaturation Effects 0.000 description 2
- 210000005069 ears Anatomy 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 210000002919 epithelial cell Anatomy 0.000 description 2
- 210000004907 gland Anatomy 0.000 description 2
- 210000004969 inflammatory cell Anatomy 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 210000004877 mucosa Anatomy 0.000 description 2
- 210000004400 mucous membrane Anatomy 0.000 description 2
- 230000017074 necrotic cell death Effects 0.000 description 2
- 238000012856 packing Methods 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 238000011020 pilot scale process Methods 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000002335 preservative effect Effects 0.000 description 2
- 210000002345 respiratory system Anatomy 0.000 description 2
- 238000005070 sampling Methods 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- COXVTLYNGOIATD-HVMBLDELSA-N CC1=C(C=CC(=C1)C1=CC(C)=C(C=C1)\N=N\C1=C(O)C2=C(N)C(=CC(=C2C=C1)S(O)(=O)=O)S(O)(=O)=O)\N=N\C1=CC=C2C(=CC(=C(N)C2=C1O)S(O)(=O)=O)S(O)(=O)=O Chemical compound CC1=C(C=CC(=C1)C1=CC(C)=C(C=C1)\N=N\C1=C(O)C2=C(N)C(=CC(=C2C=C1)S(O)(=O)=O)S(O)(=O)=O)\N=N\C1=CC=C2C(=CC(=C(N)C2=C1O)S(O)(=O)=O)S(O)(=O)=O COXVTLYNGOIATD-HVMBLDELSA-N 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 235000005979 Citrus limon Nutrition 0.000 description 1
- 244000131522 Citrus pyriformis Species 0.000 description 1
- 235000016623 Fragaria vesca Nutrition 0.000 description 1
- 240000009088 Fragaria x ananassa Species 0.000 description 1
- 235000011363 Fragaria x ananassa Nutrition 0.000 description 1
- 206010017553 Furuncle Diseases 0.000 description 1
- 206010020565 Hyperaemia Diseases 0.000 description 1
- 206010020741 Hyperpyrexia Diseases 0.000 description 1
- XINCECQTMHSORG-UHFFFAOYSA-N Isoamyl isovalerate Chemical compound CC(C)CCOC(=O)CC(C)C XINCECQTMHSORG-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010054826 Pharyngeal lesion Diseases 0.000 description 1
- 235000014676 Phragmites communis Nutrition 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- UEDUENGHJMELGK-HYDKPPNVSA-N Stevioside Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UEDUENGHJMELGK-HYDKPPNVSA-N 0.000 description 1
- 206010046306 Upper respiratory tract infection Diseases 0.000 description 1
- 208000038016 acute inflammation Diseases 0.000 description 1
- 230000006022 acute inflammation Effects 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 238000010924 continuous production Methods 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 238000004134 energy conservation Methods 0.000 description 1
- 239000002662 enteric coated tablet Substances 0.000 description 1
- 210000003979 eosinophil Anatomy 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 229960003699 evans blue Drugs 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 239000002932 luster Substances 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000004064 recycling Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000029219 regulation of pH Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 208000020029 respiratory tract infectious disease Diseases 0.000 description 1
- 238000006748 scratching Methods 0.000 description 1
- 230000002393 scratching effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000008925 spontaneous activity Effects 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 229940013618 stevioside Drugs 0.000 description 1
- OHHNJQXIOPOJSC-UHFFFAOYSA-N stevioside Natural products CC1(CCCC2(C)C3(C)CCC4(CC3(CCC12C)CC4=C)OC5OC(CO)C(O)C(O)C5OC6OC(CO)C(O)C(O)C6O)C(=O)OC7OC(CO)C(O)C(O)C7O OHHNJQXIOPOJSC-UHFFFAOYSA-N 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/288—Taraxacum (dandelion)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/19—Acanthaceae (Acanthus family)
- A61K36/195—Strobilanthes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/31—Brassicaceae or Cruciferae (Mustard family), e.g. broccoli, cabbage or kohlrabi
- A61K36/315—Isatis, e.g. Dyer's woad
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/539—Scutellaria (skullcap)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/66—Papaveraceae (Poppy family), e.g. bloodroot
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/53—Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Neurosurgery (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The present invention relates to a kind of Chinese medical extract and its pharmaceutical preparation and preparation method, more particularly to a kind of blue anti-inflammatory syrup in children Pu ground and preparation method thereof.A kind of preparation method of blue extract in Pu ground with antiinflammation that the present invention is provided, the method by 3.0 5.0 parts of raw material common dandelion by weight, 1.0 2.0 parts of Radix Isatidis, the 1.0 2.0 parts of water extractions of 0.5 1.5 parts of corydlis bungeana and the root of large-flowered skullcap, alcohol precipitation afterwards.The method that the present invention prepares the blue extract in Pu ground is full prescription water extraction, process is simple, beneficial to production.The blue anti-inflammatory syrup good stability in children Pu ground of present invention preparation, in good taste, bioavilability are high.The medicine has clearing heat and detoxicating, anti-inflammatory or detumescence effect, for treating the diseases such as parotitis, pharyngitis and tonsillitis.
Description
Technical field
The present invention relates to a kind of Chinese medical extract and its pharmaceutical preparation and preparation method, more particularly to a kind of children Pu Dilan
Anti-inflammatory syrup and preparation method thereof.
Background technology
Mumps, acpuei pharyngitis and tonsillitis are children's common disease, and mumps belongs to infectious
Disease, it is common bacillary and viral.It is referred to as mumps in the traditional Chinese medical science；Hu Yongmei is in " Chinese 2010-2012 mumps stream
Summed up in row venereology signature analysis " and be respectively in continuous 3 years of the mumps incidence of disease 22.3963/10 ten thousand,
33.8363/10 ten thousand, 35.5897/10 ten thousand, wherein less than 15 years old age account for respectively total case load then 91.58%,
90.93%th, 90.27%.Tonsillitis belongs to the infection of the upper respiratory tract, because infant's respiration systematic growth is still immature, immunity of organism
System also imperfection, resistance is relatively low compared with adult.Current acute upper respiratory infection is the first place of infant infectious diseases, and
The incidence of disease highest of acute tonsillitis, it is most commonly seen with virus infection, the category of " acute tonsillitis " is belonged in the traditional Chinese medical science, it is due to exopathogen
Invasion and attack, it is upper to violate throat or lung and stomach excessive heat, above to attack caused by throat, children's symptom is relatively grown up again, is often accompanied by hyperpyrexia.Pharyngitis is also
Category the infection of the upper respiratory tract, the incidence of disease is also higher in children, especially acpuei pharyngitis, be swallow mucous membrane, sub-mucosal tissues it is acute
Inflammation.Traditional Chinese medicine thinks that acpuei pharyngitis belongs to acute throat obstruction category, and cause is similar with acute tonsillitis, and major lesions internal organs exist
Lung, stomach, it is clinical common with wind-heat disease card, lung and stomach excessive heat card.
At present, doctor trained in Western medicine is treating such illness more with antibiotic therapy, as antibiotic resistance is increasingly serious so that in
Treatment day aobvious advantage of the medicine to such illness.Though really effectively, side effect is larger for antibiotic therapy, easily recurrence.The traditional Chinese medical science is recognized
Preferably clearing heat and detoxicating to treat such illness, relieving sore-throat of subsiding a swelling, therapy curative effect is safe and reliable, and few side effects, promotional value is big.Pu ground is blue
Anti-inflammatory oral liquid is to have listed kind, with clearing heat and detoxicating, relieving sore-throat of subsiding a swelling.For furuncle, parotitis, pharyngitis, tonsillitis.It is many
Year clinical display, the kind equally has preferable market in paediatrics, but the blue anti-inflammatory oral liquid in Pu ground is not specific on usage and dosage
Children's usage and dosage is referred to, children is only referred to and is cut down according to the circumstance.During Clinical practice find, oral liquid for children, mouthfeel
Poor, child administration is more difficult, therefore, a kind of new pharmaceutical preparation for being suitable for child administration is developed on this basis particularly
It is important.Syrup is the dense aqueous sucrose solution containing medicine or aromatic substance, and for orally using, sucrose and aromatic etc. can be covered
The bad smell of medicine, improves taste, is especially welcome by children.The easy microbial contamination of syrup, it is main attached in syrup
Plus agent is preservative, the sensitive group in body development particular time such as children, pregnant woman, inedibility those excessive uses are prevented
The food of rotten agent.The root of large-flowered skullcap needs individually to extract in the blue anti-inflammatory oral liquid technique in Pu ground simultaneously, and technique is complex.
The content of the invention
It is an object of the present invention to provide a kind of blue extract in Pu ground with antiinflammation and preparation method thereof, should
Method is full prescription water extraction, process is simple, beneficial to production.
It is another object of the present invention to provide blue anti-inflammatory syrup in a kind of children Pu ground and preparation method thereof, the syrup
In good taste, good stability, bioavilability are high.
It is also an object of the present invention to provide the purposes of the blue anti-inflammatory syrup medicine in above-mentioned children Pu ground.
A technical scheme of the invention is, there is provided a kind of preparation method of the blue extract in Pu ground with antiinflammation,
The method is comprised the following steps：
1) water extraction：By 3.0-5.0 parts of raw material common dandelion by weight, Radix Isatidis 1.0-2.0 parts, corydlis bungeana 0.5-
1.5 parts and root of large-flowered skullcap 1.0-2.0 parts of water extraction, after wherein dandelion, Radix Isatidis, corydlis bungeana boil in water, the root of large-flowered skullcap are put into, water extraction
Obtain Aqueous extracts；
2) alcohol precipitation：Concentration Aqueous extracts to 60-70 DEG C of heat of relative density surveys 1.10-1.15, adds absolute ethyl alcohol, makes concentration
The volume content of ethanol is 60% in Aqueous extracts, filters off insoluble matter, and the solvent removed in filtrate obtains extract.
Preferably, wherein described bulk drug is 1.5 parts of 4 parts of dandelion, 1.5 parts of Radix Isatidis, 1.0 parts of corydlis bungeana and the root of large-flowered skullcap
It is full prescription water extraction in the present invention, full prescription water extraction is by four kinds of bulk drugs in formula：Dandelion, Radix Isatidis,
Corydlis bungeana and the disposable water extraction of the root of large-flowered skullcap, it is not necessary to by the independent water extraction of the root of large-flowered skullcap.
Water extraction water weight of the present invention is decoct bulk drug 10 times, is decocted 3 times altogether, each 1.5h, merges each
Secondary fried liquid.
The time placed after ethanol is added to be preferably 24h in alcohol precipitation step of the present invention.
The invention provides a kind of blue extract in Pu ground with antiinflammation, it is prepared by the above method.
Another technical scheme that the present invention is provided is to provide a kind of blue anti-inflammation drugs in Pu ground, and it is by as active component
The above method prepare extract and pharmaceutically acceptable auxiliary material composition.
The blue anti-inflammation drugs in Pu ground of the invention, it is syrup, i.e. the blue anti-inflammatory syrup in Pu ground.
The sweetener included in the blue anti-inflammatory syrup in Pu ground of the invention is the one kind in sucrose, steviol glycoside and Sucralose
Or it is various；
Preferably, the sweetener for being included in the blue anti-inflammatory syrup in Pu ground is sucrose, steviol glycoside and Sucralose；
It is highly preferred that the content of the sweetener in the blue anti-inflammatory syrup in Pu ground is sucrose 45% (g/mL), steviol glycoside 0.2%
And Sucralose 0.1% (g/mL) (g/mL).
The blue anti-inflammation drugs syrup in Pu ground of the invention also includes essence；
Preferably, essence is flavoring orange essence；
It is highly preferred that the blue syrup bag in Pu ground (g/mL) containing flavoring orange essence 0.15%.
The blue anti-inflammatory syrup in Pu ground in the present invention, by dandelion 500g, Radix Isatidis 188g, corydlis bungeana 125g, root of large-flowered skullcap 188g
It is prepared from, preparation method comprises the steps：
1) water extraction：After dandelion, Radix Isatidis, corydlis bungeana boil in water, the root of large-flowered skullcap is put into, water extraction obtains Aqueous extracts；
2) alcohol precipitation：Extract solution is concentrated into the clear cream that 60~70 DEG C of heat of relative density survey 1.10~1.15, adds absolute ethyl alcohol,
Make the volume content of ethanol in the Aqueous extracts of concentration be 60%, stand 24h, filtering, supernatant removes ethanol to relative density 60
~70 DEG C of medicinal extract of heat survey 1.15~1.20；
3) to 700mL is added water in medicinal extract, 48h is refrigerated, filtering, supernatant sodium hydroxide solution adjusts pH value to 6.5, plus
Enter sucrose 450g, steviol glycoside 2g, Sucralose 1g, boil, filter, add 1.5g flavoring orange essences, add water to 1000mL.
The blue anti-inflammatory syrup in Pu ground prepared by the present invention is without stabilizer and preservative, and the blue anti-inflammatory syrup in Pu ground of preparation is clear
Clearly, good stability, bioavilability are high.
The blue anti-inflammatory syrup good mouthfeel in Pu ground prepared by the present invention, improves the compliance of children, is adapted to child administration.
The stability of Cichoric acid is affected by many factors, such as pH value, temperature, and scutelloside is dissolved in aqueous slkali, but
It is unstable in aqueous slkali, gradual change burgundy, the blue anti-inflammatory syrup in Pu ground that the present invention is provided, its active component Cichoric acid and scutelloside
Being capable of stable existence, and good mouthfeel.
Extract prepared by the present invention is used as preparation treatment Child epidemic parotitis, acpuei pharyngitis or acute tonsillitis
The application of medicine.
The preparation method of extract of the present invention is full prescription water extraction, process is simple, beneficial to production, by the small of extract preparation
The blue anti-inflammatory syrup in youngster Pu ground has good stability, clear, in good taste, bioavilability high, stable preparation process, green
Color energy-conservation.
Brief description of the drawings
Fig. 1 is pharyngeal pathologic examination picture.
Specific embodiment
This can be further well understood to by the specific embodiment and comparing embodiment of invention now given below
Invention.But they are not limitation of the invention.
Embodiment 1
1 medicinal material extraction process by water is preferred
1.1 orthogonal preferred extraction process by water
L is carried out by Three factors-levels to amount of water, extraction time, extraction time9(34) orthogonal design preferably goes out optimal water
Put forward process conditions.
The water extraction orthogonal test factor level table of table 1
Each 9 parts of dandelion 50g, Radix Isatidis 18.8g, corydlis bungeana 12.5g, root of large-flowered skullcap 18.8g is taken, by L9(34) orthogonal arrage carries out
Experiment, is the preferably optimal extraction process by water of index with the content of scutelloside and Cichoric acid, the results are shown in Table 2~4.
The Orthogonal Experiment and Design of table 2 and result table
The water extraction scutelloside analysis of variance table of table 3
The water extraction Cichoric acid analysis of variance table of table 4
C is as index analysis result factor influence size order directly perceived with scutelloside, witloof acid content>B>A；Scutelloside
The results of analysis of variance, factor C has pole conspicuousness influence, and optimum extraction process is A2B3C3I.e. plus 10 times amount water, extract three times, often
Secondary 2h.Cichoric acid the results of analysis of variance, factor C has significant difference, and optimum extraction process is A3B3C3I.e. plus 12 times amount water, carry
Take three times, each 2h.Due to B3With B2Content of baicalin difference is smaller；A3With A2, B3With B2Cichoric acid content difference is smaller.It is comprehensive
Close and consider, determine that optimised process is：A2B2C3, that is, add 10 times of amount water to extract 3 times, each 1.5h.
1.2 water extraction checking techniques
Dandelion 250g, Radix Isatidis 94g, corydlis bungeana 62.5g, root of large-flowered skullcap 94g are taken respectively, it is preferably optimal according to orthogonal test
Scheme carries out 3 checking tests.
The water extraction checking test result of table 5
Understand from the above, 3 checking scutelloside average contents are that 87.0mg/g- crude drugs, RSD are 0.78%, witloof
Sour average content is 0.899mg/g- crude drugs, RSD is 2.47%, illustrates that preferred extraction process by water stablizes feasible.
Embodiment 2
1 Aqueous extracts alcohol precipitation process is preferred
1.1 orthogonal optimization alcohol precipitation processes
L is carried out by Three factors-levels to medicinal extract relative density, alcohol precipitation concentration and alcohol precipitation time9(34) orthogonal design is preferred
Go out optimal alcohol precipitation process.
The alcohol precipitation orthogonal test factor level table of table 6
The extract solution filtering that water extraction is verified, merges, and 3 parts are divided into after being concentrated into relative density 1.05~1.10：The
Portion is divided into 3 parts again；Second part is continued to be divided into 3 parts again after being concentrated into relative density 1.10~1.15；3rd part after
Continue and be divided into 3 parts again after being concentrated into relative density 1.15~1.20.By L9(34) orthogonal test table carries out alcohol precipitation experiment, with Huang
A kind of reed mentioned in ancient books glycosides and witloof acid content are intuitively analyzed and variance analysis for inspection target, the results are shown in Table 7~9.
The alcohol precipitation orthogonal test table of table 7
The alcohol precipitation scutelloside analysis of variance table of table 8
The alcohol precipitation Cichoric acid analysis of variance table of table 9
B is as index analysis result factor influence size order directly perceived with scutelloside, witloof acid content>A>C；Scutelloside
The results of analysis of variance, factor B has a significant impact, and without influence, optimal alcohol precipitation process is A to factor A, C1B1C2I.e. medicinal extract is relatively close
Degree 1.05-1.10, alcohol precipitation concentration is 60%, alcohol precipitation 24h.Cichoric acid the results of analysis of variance, factor B has pole significant difference, because
, without influence, optimal alcohol precipitation process is A for plain A, C2B1C3That is medicinal extract relative density 1.10-1.15, alcohol precipitation concentration is 60%, alcohol precipitation
48h.Due to A1It is larger to alcohol precipitation process influence, precipitate shaky, it is more difficult to filter, consider, it is final to determine that alcohol precipitation process is
A2B1C2, i.e. medicinal extract relative density 1.10-1.15, alcohol precipitation concentration is 60%, alcohol precipitation 24h.
1.2 alcohol precipitation checking techniques
Each 3 parts of dandelion 300g, Radix Isatidis 112.8g, corydlis bungeana 75g, root of large-flowered skullcap 112.8g is taken to be carried according to optimal extraction process by water
Take, 3 alcohol precipitation checking tests are carried out further according to the preferred preferred plan of alcohol precipitation orthogonal test.
The alcohol precipitation checking test result of table 10
Understand from the above, 3 alcohol precipitation checking scutelloside average contents are that 52.74mg/g, RSD are 1.24%, witloof
Sour average content is that 0.652mg/g, RSD are 0.94%, shows that the preferred process stabilizing of alcohol precipitation is feasible.
Embodiment 3
1. cold preservation time screening
On the basis of preliminary experiment, a certain amount of alcohol precipitation supernatant is taken, it is 1.15~1.20, average mark to be concentrated into relative density
Into four parts, the 70% of recipe quantity is added water to respectively, 24h, 36h, 48h, 72h are placed in refrigeration respectively, carry out scutelloside and Cichoric acid
Comparision contents, and sample clarity is investigated simultaneously.
The cold preservation time the selection result of table 11
Understand from the above, with the increase of cold preservation time, the content of scutelloside and Cichoric acid is gradually reduced, but sample
Clarity is still undesirable, and when cold preservation time is more than 48h, sample clarity slightly makes moderate progress, therefore selection cold preservation time is
48h, is intended to optimize clarity on this basis.
Embodiment 4
1. adjustment PH techniques are preferred
The screening of PH is carried out to the sample liquid after refrigeration, because scutelloside is unstable in the basic conditions, therefore when investigating PH≤7 not
Influence with value to preparation result.Sample liquid after 5 parts of refrigerations of equivalent is taken, its PH is adjusted to 5.0,5.5,6.0,6.5,7.0 respectively, point
Do not add 50% sucrose, boil, filter, add water to recipe quantity, filling, sterilizing, determine respectively before sterilizing with sterilizing after sample
Scutelloside and witloof acid content, and the PH of sample after sterilizing is determined, and the clarity of sample is observed, it is determined that optimal pH value.
Table 12 adjusts PH technological experiment results
Understand from the above：PH5.0,5.5 samples are adjusted, still there is a small amount of precipitation after sterilizing；When adjusting more than PH6.0, sample
Clarity gradually improves, but with increasing that pH value is adjusted, PH falls gradually increase in its sample, and scutelloside, witloof
Acid content is gradually reduced, and is considered, and determines PH regulation techniques to be adjusted to 6.5.
Embodiment 5
1.1 sweetener species are screened
Conventional sweetener mainly has sucrose, honey element, steviol glycoside and Sucralose in the market.Wherein stevioside
The sugariness of glycosides is 200~300 times of sucrose, and calorific value is only the 1/300 of sucrose.The sugariness of honey element is 30~40 times of sucrose.
The sugariness of Sucralose is about 600 times of sucrose, and sweet taste is pure, and sweet taste characteristic is quite similar with sweet taste quality and sucrose.
《Chinese Pharmacopoeia》Syrup is defined as：Amount containing sucrose should be not less than 45% (g/mL).It is sweet due to honey element
Degree is relatively low, therefore, this experiment is compared research to sucrose, steviol glycoside and Sucralose, using mouthfeel as inspection target, really
Determine sweetener type.
The sweetener species the selection result of table 13
Result of the test shows：Only add the syrup mouthfeel of sucrose very poor；Add a kind of sweet taste again on the basis of sucrose is added
Agent, its mouthfeel is also poor；The syrup for adding sucrose, steviol glycoside and Sucralose to prepare simultaneously, its mouthfeel is relatively good.
1.2 sweetener consumptions are screened
Consumption to above-mentioned sweetener is screened, and using mouthfeel as inspection target, determines the consumption of sweetener.
The sweetener consumption the selection result of table 14
Result of the test shows：The consumption of steviol glycoside, Sucralose and sucrose is respectively 0.2% (g/mL), 0.1% (g/
ML) and when 45% (g/mL), the mouthfeel sweet taste of syrup is moderate, relatively preferably, it is thus determined that three kinds of consumptions difference of sweetener
It is sucrose 45% (g/mL), steviol glycoside 0.2% (g/mL), Sucralose 0.1% (g/mL).
Embodiment 6
1.1 essence species are screened
Further to improve the smell and mouthfeel of preparation, it is intended to adding a small amount of essence in the formulation.This experiment is fragrant to orange
Essence, strawberry essence, flavoring apple essence, lemon extract, chocolate essence and butter essence are compared research, using mouthfeel as investigation
Index, determines the type and consumption of essence.
The essence species the selection result of table 15
Result of the test shows：The mouthfeel of flavoring orange essence is more pure and fresh and can cover the certain bitter taste of syrup, more fragrant than other
Essence is in good taste, therefore selects flavoring orange essence.
1.2 essence consumptions are screened
It is determined that on the basis of essence species, the consumption to essence is screened, using mouthfeel as inspection target, it is determined that fragrant
The consumption of essence.
The essence consumption result of table 16
Result of the test shows：The consumption of flavoring orange essence is good in taste when being 0.15% (g/mL).
Embodiment 7
1. the preparation of syrup
Dandelion 500g, Radix Isatidis 188g, corydlis bungeana 125g, root of large-flowered skullcap 188g, the root of large-flowered skullcap are added after water boils, plus 10 times of weights
Amount decocting is boiled three times, each 1.5h, filtering, merging filtrate, and it is that 60~70 DEG C of heat survey 1.10~1.15 to be concentrated into relative density
Clear cream, plus ethanol makes its volume content be 60%, places 24h, and filtering, filtrate recycling ethanol to 60~70 DEG C of heat of relative density is surveyed
1.15~1.20,700mL is added water to, 48h is refrigerated, filtering, filtrate adjusts pH value to 6.5 with 10% sodium hydroxide solution, adds
450g sucrose, the steviol glycoside of 2g, 1g Sucraloses, boil, filtering, add 1.5g flavoring orange essences, add water to 1000mL, stir
Mix, dispense, sterilize 30min, obtains final product.
It is prepared as described above technique and has carried out the 3 batches of pilot-scales amplifying checking, feeds intake 3 batches, lot number is respectively 150621,
150622nd, 150623, production technology pilot scale data are shown in Table 17.
The big creation data of table 17
* note：150621 batches of samples, it is 300 times of prescriptions to extract batch, wherein 100 times of prescription medicinal extract are tested for pharmacological toxicology
With；200 times of prescription medicinal extract supply quality research, stability test to use with liquid.150622nd, 150623 batches of samples supply stability test
With.
Scutelloside and witloof acid content are relatively stable in three batches of samples (lot number 150621,150622,150623), show this
The continuous production stability of technique is good, and process conditions are easily-controllable, feasible, is adapted to industrialized production.
Embodiment 8
Stability test
1.1 investigate project
Table 18 investigates project
1.2 accelerated tests
Take the blue big production scale sample of the anti-inflammatory syrup (all batches in " sample source ") in children Pu ground and be placed in temperature 40 ± 2
DEG C, place 6 months in the climatic chamber of relative humidity 75% ± 5%.In the respectively sampling detection one of the 0th, 1,2,3,6 the end of month
It is secondary, detected that testing result is specific to try compared with 0 day with quality standard according to the blue anti-inflammatory syrup report production in children Pu ground
Test and the results are shown in Table 19~21.
Table 19 accelerates the investigation result (lot number that keeps sample：150621)
Table 20 accelerates the investigation result (lot number that keeps sample：150622)
Table 21 accelerates the investigation result (lot number that keeps sample：150623)
From table 19~21, three batches of observed samples, under the terms of packing of regulation, through 40 ± 2 DEG C of temperature, relative
Placed 6 months in the climatic chamber of humidity 75% ± 5%, compared with 0 day, proterties, discriminating, relative density, pH value, microorganism
Limit, content of baicalin are almost unchanged.The content of Cichoric acid is declined slightly, and 0.15mg/mL is fallen to approximately by 0.17mg/mL.
But every testing result meets standard regulation.
1.3 long term tests
Long term test：The blue big production scale sample of the anti-inflammatory syrup (all batches in " sample source ") in children Pu ground is taken to be placed in
Placed 18 months in 25 ± 2 DEG C of temperature, the climatic chamber of relative humidity 60% ± 10%.In the 0th, 3,6,9,12,18 months
Last each sampling once, is detected that testing result is compared with 0 day with quality standard according to the blue anti-inflammatory syrup report clinic in children Pu ground
Compared with specific test result is shown in Table 22~24.
Table 22 keeps sample investigate result (lot number for a long time：150621)
Table 23 keeps sample investigate result (lot number for a long time：150622)
Table 24 keeps sample investigate result (lot number for a long time：150623)
From table 22~24, three batches of observed samples, under the terms of packing of regulation, through 25 ± 2 DEG C of temperature, relative
Placed 18 months in the climatic chamber of humidity 60% ± 10%, compared with 0 day, proterties, discriminating, relative density, pH value, micro- life
Thing limit, content of baicalin, witloof acid content are substantially unchanged, and every testing result meets standard regulation.
Embodiment 9
Statistical method in the present embodiment：
Data result represents that the comparison in difference between each group uses Graphpad with mean ± standard deviation (mean ± SD)
Compare between the one-way ANOVA analysis methods of the softwares of Prism 5, group and use Dunnett ' s to check, P ＜ 0.05 have statistics
Meaning.
Test medicine and positive drug in the present embodiment：
The blue syrup drug effect medicinal extract in children Pu ground, is provided, lot number by Jumpcan Pharmaceutical Group Co., Ltd.：150621.1g soaks
Cream is equivalent to 3.5g crude drugs.Finished product children day take crude drug total amount and are：15g crude drugs/person/day.
Aspirin enteric coated tablet (visits aspirin), Bayer Health Care Manufacturing S.r.l, rule
Lattice：100mg/ pieces, lot number：BJ22790.
Pentoxyverine sheet (carbetapentane citrate), Pharmaceutical Group Rong Sheng pharmaceutical Co. Ltds, specification：25mg/ pieces, 100/
Bottle, lot number：14061722.
1. the blue syrup dose design in Pu ground
The rat dosage of table 25
The mouse dose of table 26
The cavy dosage of table 27
2. the blue syrup in Pu ground causes the influence of rat acute pharyngitis to ammoniacal liquor
2.1 experimental animals
SD rats, SPF grades, body weight 120-150g, 72, female half and half, purchased from Zhejiang Province's Experimental Animal Center, is tested dynamic
Thing production licence number：SCXK (Zhejiang) 2014-0001.Rat sub-cage rearing, fed granules feed, 22 ± 2 DEG C of room temperature, humidity
50%-67%, free water, illumination appropriateness, adaptability is standby after feeding.
2.2 methods
2.2.1 the foundation of rat acute pharyngitis model
SPF grades of SD rat, male and female half and half, with laryngeal spray in the pharyngeal ammoniacal liquor of sprinkler body fraction 15% of rat, spray 3 every time
Press, at each 1 time of daily upper and lower noon, continuous 4d causes acpuei pharyngitis model；Daily observed and recorded each group animal appearance state, and see
The pharyngeal situation of animal is examined, including Mucosa Morphology, color and luster etc..
2.2.2 animal packet and dosage regimen
SD rats 72, male and female half and half are randomly divided into 6 groups, respectively every group 12, blank group, model group, sun by body weight
Property medicine group, Pu ground indigo plant 0.45g/kg, 1.35g/kg, 4.05g/kg.Each group rat starts gavage and gives corresponding dosage medicine in d1,
Blank group gives the physiological saline of same volume, once a day, continuous 7 days with model group.In addition to blank group, d5-d7 uses volume
The ammonia spraying of fraction 15% replicates SD rat acute pharyngitis models, and blank group sprays isometric physiological saline, twice daily.
2.3 experimental results
2.3.1 rat behavior observation
After to rat spray ammoniacal liquor, there is oral area of scratching in most of rats, and oral secretion increases, and drinking-water increases, under appetite
The phenomenons such as drop, spontaneous activity reduction.After ammoniacal liquor modeling 4 days, model group rats are pharyngeal to there is hyperemia, in kermesinus, micro- swelling,
Administration group rat symptom mitigates in various degree compared with model group.
2.3.2 blood routine testing result
Compared with blank group, model group monocyte and neutrophil leucocyte percentage composition increased, and lymphocyte is
Decline, and eosinophil percentage composition is without significant change.The blue syrup various dose group in Pu ground can in various degree reduce monokaryon
Cell and neutrophil leucocyte percentage composition, increase lymphocyte percentage composition, but without significant difference between each group；Medicine is to acidophilus
Property granulocyte percentage composition has no significant effect.
The blood routine testing result of table 28
2.3.3 in pharyngeal IL-6 expression
After being sprayed through ammoniacal liquor throat, IL-6 expressions are significantly raised compared with blank group in rat pharyngeal mucosa tissue, Pu Di
Blue syrup 0.45g/kg can substantially lower IL-6 contents.
The expression of IL-6 in the pharyngeal of table 29
Note：Compare with blank group,##P<0.01；Compare with model group, * P<0.05, * P<0.05.
2.3.4 pharyngeal pathologic examination
By stratified squamous epithelium, upper subcutaneous have thin layer connective tissue to the pharyngeal mucous membrane table of normal rat, it is seen that mucous gland is mixed
Gland is closed, mucosal epithelial cells are without denaturation, necrosis, upper intracutaneous and upper subcutaneous without cell infiltration.Model group majority pharyngeal wall tissue is light
Degree is congested, and pharyngeal mucosal epithelial cells are slight or moderate denaturation, necrosis, and upper intracutaneous or pharynx wall have slight or moderate inflammatory cell to soak
Profit, inflammatory cell type is based on neutrophil leucocyte.Pu ground indigo plant syrup 4.05g/kg can make the pharyngeal non-cancer lesion degree of rat obvious
Mitigate.
The pharyngeal lesion score result (mean ± SD) of the rat of table 30
Note：Compare with blank group,##P<0.01；Compare with model group,*P<0.05。
The expression and pharyngeal pathologic group of IL-6 from rat behavior observation, blood routine testing result, pharyngeal
Knit observation and understand that Pu bring down a fever piece has certain intervention effect to rat acute pharyngitis.
3. the blue syrup in Pu ground causes the influence of guinea pig cough to citric acid
3.1 experiment materials
3.1.1 positive drug
Pentoxyverine sheet (carbetapentane citrate), Pharmaceutical Group Rong Sheng pharmaceutical Co. Ltds, specification：25mg/ pieces, 100/
Bottle, lot number：14061722.
3.1.2 experimental animal
Baby guinea pig (8 week old), regular grade, male and female half and half, body weight 210-260g, Jiangning county Qinglongshan animal is numerous
Grow field, credit number：SCXK (Soviet Union) 2012-0008.
Cavy sub-cage rearing, fed granules feed, 22 ± 2 DEG C of room temperature, humidity 50%-67%, free water, illumination is fitted
Degree, adaptability is standby after feeding.
3.2 experimental techniques and dosage regimen
40 body weight 210-260g Baby guinea pigs (8 week old) are taken, male and female half and half are placed in the observation ward of 500mL, with constant
Pressure sprays into 17.5% citric acid, and spray 1min, observes and record cough latent period of the cavy within 5min and cough time
Number, cough number of times≤10 time in cough latent period≤10s or >=120s, and 5min or the cavy of >=50 times are all picked
Remove.The qualified cavy of pre-selection through body weight stratified random be divided into 5 groups, i.e. model group, carbetapentane citrate group, the blue syrup in children Pu ground it is low, in,
High dose group (0.39g/kg, 1.16g/kg, 3.49g/kg), every group 6.Each group continuous gavage is administered 7 days, once a day, mould
Type group cavy is filled with isometric distilled water.1h after last dose, is drawn by above-mentioned screening conditions and coughs cavy, is observed and is recorded cavy and cough
The cough number of times coughed in incubation period and 5min.
3.3 results
Compared with model group, the blue basic, normal, high dosage of syrup in children Pu ground can in various degree extend and draw the cough for coughing cavy and dive
Volt phase (P<0.05, P<0.01) it is, optimal with 3.49g/kg dosage groups；Additionally, the blue each dosage group of syrup in children Pu ground can be reduced
Draw the cough number of times (P for coughing cavy<0.001).
The blue syrup in the children Pu of table 31 ground causes the influence of guinea pig cough to citric acid
Note：Compare * P with model group<0.05, * * P<0.01, * * * P<0.001.
Drawn by cavy and cough the antitussive action that the blue syrup in Pu ground is investigated in experiment, each dosage group of syrup can be different in the experiment
Degree extends cough latent period, reduces the cough number of times that citric acid causes Baby guinea pig, illustrates that the blue syrup in children Pu ground has obvious
Antitussive action.
4. the blue syrup in Pu ground induces ammoniacal liquor the influence of mouse cough
4.1 experiment materials
4.1.1 positive drug
Pentoxyverine sheet (carbetapentane citrate), Sinopharm Group Rongsheng Pharmaceutical Co., Ltd., specification：25mg/ pieces, 100/
Bottle, lot number：14042721.
4.1.2 experimental animal
ICR mouse, cleaning grade, male and female half and half, body weight 18-22g, Yangzhou University's comparative medicine center, credit number：SCXK
(Soviet Union) 2012-0004.
Mouse sub-cage rearing, fed granules feed, 22 ± 2 DEG C of room temperature, humidity 50%-67%, free water, illumination is fitted
Degree, adaptability is standby after feeding.
4.2 experimental techniques and dosage regimen
18-22g ICR mouse 60, male and female half and half are randomly divided into 5 groups, i.e. model group, carbetapentane citrate group, Pu Di by body weight
The blue basic, normal, high dosage group of syrup (0.65g/kg, 1.95g/kg, 5.85g/kg).Each group continuous gavage is administered 7 days, daily one
Secondary, model group mouse is filled with isometric distilled water.1h after last dose, an inverted volume is placed in for 2L by mouse, and built-in one
In the beaker of cotton balls, timing is being started to when 25% concentrated ammonia liquors of 0.5mL are added dropwise on cotton balls, observing and record mouse cough and hide
Cough number of times in phase and 3min.
Compared with model group, the blue low middle high dose of syrup in Pu ground can substantially reduce cough number of times (P in mouse 3min<
0.05th, P ＜ 0.01, P<0.001) cough latent period (P can, and during 5.85g/kg dosage be obviously prolonged<0.05).
The blue syrup in the children Pu of table 32 ground causes the influence of mouse cough to ammoniacal liquor
Note：Each group compares with model group, * P<0.05, * * P<0.01, * * * P<0.001.
Drawn by mouse and cough the antitussive action that the blue syrup in Pu ground is investigated in experiment.Result of study shows, in the small of ammoniacal liquor induction
In mouse cough experiment, syrup 5.85g/kg can significantly reduce mouse cough number of times, and extend the incubation period of cough, point out Pu Dilan
Syrup has obvious antitussive action.
5. the blue syrup paraxylene in Pu ground causes the influence of mice ear
5.1 experimental animals
ICR mouse, cleaning grade, male and female half and half, body weight 18-22g, Yangzhou University's comparative medicine center, credit number：SCXK
(Soviet Union) 2012-0004.
5.2 experimental techniques and dosage regimen
ICR mouse, male and female half and half, after adaptability is raised under normal condition, 6 groups are randomly divided into by body weight by totally 72, i.e., empty
White group, model group, aspirin group, the blue basic, normal, high dosage group of the syrup (0.65g/kg, 1.95g/kg, 5.85g/kg) in Pu ground.
Gavage gives relative medicine to each group mouse respectively, and administered volume is 0.1mL/10g, and blank group and model group give isometric distillation
Water, one time a day, continuous 7d.1h after last dose, in addition to blank group, each group mouse right ear microsyringe uniform application two
Toluene, 30 μm/only, and after causing inflammation 30min, mouse ears thickness is measured with feeler, calculate left and right Er Er thick poor.Beat and take ear circle
Piece, diameter 0.8cm claims ear disk weight, calculates the ears ear method of double differences.
The blue paraxylene in 5.3 Pus ground causes the influence of mice ear model ear swelling degree
Model group mouse is thick compared with blank group ear and ear dramatically increases (P again<0.001), Pu ground indigo plant syrup 1.95g/kg with
5.85g/kg significantly mitigates mouse ear thickness (P<0.001), and 5.85g/kg groups also can substantially mitigate mouse ear weight (P<0.05).
The blue paraxylene in the Pu of table 33 ground causes the influence of mice ear model ear swelling degree
Note：###P<0.001 compares with blank group；*P<0.05, * * P<0.01 compares with model group.
The antiinflammatory action of the blue syrup in Pu ground is investigated in this experiment using mice caused by dimethylbenzene xylene ear swelling model.Result of study shows
Show, Pu ground indigo plant can obviously relieve model mice ear thickness, point out the blue syrup in Pu ground that there is certain antiinflammatory action.
6. influence of the blue syrup in Pu ground to mouse peritoneal capillary permeability
6.1 experimental animals
ICR mouse, cleaning grade, male and female half and half, body weight 18-22g, Yangzhou University's comparative medicine center, credit number：SCXK
(Soviet Union) 2012-0004.
Mouse sub-cage rearing, fed granules feed, 22 ± 2 DEG C of room temperature, humidity 50%-67%, free water, illumination is fitted
Degree, adaptability is standby after feeding.
6.2 experimental techniques and dosage regimen
18-22g ICR mouse 60, male and female half and half are layered and are divided into 5 groups, i.e. model group, aspirin group at random by body weight
The blue basic, normal, high dosage group of the syrup (0.65g/kg, 1.95g/kg, 5.85g/kg) in (400mg/kg), Pu ground, administered volume
0.1mL/10g.Each group continuous gavage is administered 7 days, and once a day, model group mouse is filled with isometric distilled water.
1h after last dose, the Evans blue normal saline solution 0.1mL/10g of tail vein injection 2%, immediately intraperitoneal injection
0.6% acetic acid normal saline solution 0.2mL/ only, puts to death after 30min, opens abdominal cavity, with 6mL brines abdominal cavity, suctions out
Cleaning solution, centrifuging and taking supernatant (3000r/min) determines optical density OD values in 590nm.
6.3 experimental results
Compared with model group, Pu ground indigo plant syrup 5.85g/kg and 1.95g/kg can suppress acetic acid and cause mouse capillary to lead to
The increase of permeability, and 5.85g/kg dosage groups have compared significant difference (P with model group<0.05).
Influence of the blue syrup in the Pu of table 34 ground to mouse capillary permeability
Note：Each group compares with model group, * P<0.05.
With investigating Pu blue syrup Dichlorodiphenyl Acetate is tested by mouse peritoneal capillary permeability causes mouse capillary penetrating
The increased inhibitory action of property.Result of study shows that Pu ground indigo plant syrup 1.95g/kg and 5.85g/kg can significantly reduce mouse capillary
Vasopermeability, points out the blue syrup in Pu ground to reduce local aseptic inflammation and ooze out by suppressing capillary permeability
So as to play antiinflammatory action.
Pharmacodynamics test result of study shows that there is the blue anti-inflammatory syrup in children Pu ground certain intervention to make to rat acute pharyngitis
With；The incubation period that citric acid causes guinea pig cough can be extended, guinea pig cough's number of times is reduced；Also ammoniacal liquor can be extended and induces mouse cough
Incubation period, with significant antitussive action；Paraxylene causes mice ear to improve significantly, with certain anti-inflammatory
Effect；Can reduce local aseptic inflammation and ooze out so as to play antiinflammatory action by suppressing capillary permeability.
The blue anti-inflammatory syrup in children Pu ground in the present invention has certain anti-inflammatory, antitussive action, it is adaptable to the Epidemic in children cheek
Adenositis, acpuei pharyngitis, the treatment of acute tonsillitis.Our compatibility is rationally, safely, effectively, technique and steady quality, controllable.
Claims (10)
1. a kind of preparation method of the blue extract in Pu ground with antiinflammation, the method is comprised the following steps：
1) water extraction：By 3.0-5.0 parts of raw material common dandelion by weight, Radix Isatidis 1.0-2.0 parts, corydlis bungeana 0.5-1.5
Part and root of large-flowered skullcap 1.0-2.0 parts of water extraction, after wherein dandelion, Radix Isatidis, corydlis bungeana boil in water, the root of large-flowered skullcap are put into, and water extraction is obtained
To Aqueous extracts；
2) alcohol precipitation：Concentration Aqueous extracts to 60-70 DEG C of heat of relative density surveys 1.10-1.15, adds absolute ethyl alcohol, makes the water extraction of concentration
The volume content of ethanol is 60% in liquid, filters off insoluble matter, and the solvent removed in filtrate obtains extract.
2. the preparation method of the blue extract in Pu according to claim 1 ground, wherein described raw material medicaments in part by weight is calculated as
1.5 parts of 4 parts of dandelion, 1.5 parts of Radix Isatidis, 1 part of corydlis bungeana and the root of large-flowered skullcap.
3. the preparation method of the blue extract in Pu according to claim 1 ground, wherein described aqueous extraction step water weight is
10 times of bulk drug are decocted, is decocted 3 times altogether, each 1.5h, merge each fried liquid.
4. the preparation method of the blue extract in Pu according to claim 1 ground, wherein adding second in described alcohol precipitation step
24h is placed after alcohol.
5. a kind of blue extract in Pu ground with antiinflammation, its method system as described in any one in Claims 1-4
It is standby.
6. blue anti-inflammation drugs in a kind of Pu ground, its extract as described in the claim 5 as active component and can pharmaceutically connect
The auxiliary material received is constituted.
7. blue anti-inflammation drugs in Pu according to claim 6 ground, it is syrup, it is preferable that the sweetener that it is included is sugarcane
One or more in sugar, steviol glycoside and Sucralose；It is highly preferred that the content of sweetener is sucrose 45% (g/mL), sweet
Synanthrin glycosides 0.2% (g/mL) and Sucralose 0.1% (g/mL).
8. blue anti-inflammation drugs in Pu ground according to claim 6 or 7, it also includes essence；Preferably, it includes orange perfume
Essence；It is highly preferred that it includes flavoring orange essence 0.15% (g/mL).
9. the blue anti-inflammatory syrup in a kind of Pu ground, by dandelion 500g, Radix Isatidis 188g, corydlis bungeana 125g, root of large-flowered skullcap 188g is prepared from,
Preparation method comprises the steps：
1) water extraction：After dandelion, Radix Isatidis, corydlis bungeana boil in water, the root of large-flowered skullcap is put into, water extraction obtains Aqueous extracts；
2) alcohol precipitation：Extract solution is concentrated into the clear cream that 60~70 DEG C of heat of relative density survey 1.10~1.15, adds absolute ethyl alcohol, makes dense
The volume content of ethanol is 60% in the Aqueous extracts of contracting, stands 24h, and filtering, supernatant removes ethanol to relative density 60~70
DEG C heat survey 1.15~1.20 medicinal extract；
3) to 700mL is added water in medicinal extract, 48h is refrigerated, filtering, supernatant adjusts pH value to 6.5 with sodium hydroxide solution, adds sugarcane
Sugared 450g, steviol glycoside 2g, Sucralose 1g, boil, filtering, add 1.5g flavoring orange essences, add water to 1000mL.
10. extract according to claim 5 is used as preparation treatment Child epidemic parotitis, acpuei pharyngitis or acute flat
The application of peach body inflammation medicine.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710164692.7A CN106913627B (en) | 2017-03-20 | 2017-03-20 | Infantile Pudilan anti-inflammation syrup and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710164692.7A CN106913627B (en) | 2017-03-20 | 2017-03-20 | Infantile Pudilan anti-inflammation syrup and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN106913627A true CN106913627A (en) | 2017-07-04 |
| CN106913627B CN106913627B (en) | 2021-01-05 |
Family
ID=59461405
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710164692.7A Active CN106913627B (en) | 2017-03-20 | 2017-03-20 | Infantile Pudilan anti-inflammation syrup and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106913627B (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116898921A (en) * | 2023-08-10 | 2023-10-20 | 江西新世纪民星动物保健品有限公司 | Preparation method of cattail and dyer woad compound traditional Chinese medicine preparation |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1883566A (en) * | 2006-06-02 | 2006-12-27 | 江苏济川制药有限公司 | Anti-inflammation medicine and method for preparing same |
| CN101209287A (en) * | 2006-12-27 | 2008-07-02 | 天津中新药业集团股份有限公司 | Heat-clearing and detoxication antiphlogistic detumescence Chinese medicinal composition and preparation thereof |
| CN104940301A (en) * | 2015-05-31 | 2015-09-30 | 黑龙江佰彤儿童药物研究有限公司 | Pudilan children's antiviral oral pellet gel and preparation method thereof |
-
2017
- 2017-03-20 CN CN201710164692.7A patent/CN106913627B/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1883566A (en) * | 2006-06-02 | 2006-12-27 | 江苏济川制药有限公司 | Anti-inflammation medicine and method for preparing same |
| CN101209287A (en) * | 2006-12-27 | 2008-07-02 | 天津中新药业集团股份有限公司 | Heat-clearing and detoxication antiphlogistic detumescence Chinese medicinal composition and preparation thereof |
| CN104940301A (en) * | 2015-05-31 | 2015-09-30 | 黑龙江佰彤儿童药物研究有限公司 | Pudilan children's antiviral oral pellet gel and preparation method thereof |
Non-Patent Citations (1)
| Title |
|---|
| 张超云等: "《药剂学》", 31 October 2013, 辽宁大学出版社有限公司 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116898921A (en) * | 2023-08-10 | 2023-10-20 | 江西新世纪民星动物保健品有限公司 | Preparation method of cattail and dyer woad compound traditional Chinese medicine preparation |
| CN116898921B (en) * | 2023-08-10 | 2024-05-31 | 江西新世纪民星动物保健品有限公司 | Preparation method of cattail and dyer woad compound traditional Chinese medicine preparation |
Also Published As
| Publication number | Publication date |
|---|---|
| CN106913627B (en) | 2021-01-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101549061B (en) | Medicament for treating bronchitis and preparation method thereof | |
| CN106138360A (en) | A kind of Chinese medicine composition and preparation method thereof, application | |
| US10111925B2 (en) | Formulations comprising plant extracts | |
| CN104906347A (en) | Honeysuckle, smoked plum and Chinese olive lozenge as well as preparation method and application thereof | |
| CN104940301A (en) | Pudilan children's antiviral oral pellet gel and preparation method thereof | |
| CN105764519B (en) | For treating the composition based on plant of cough | |
| CN105769970A (en) | Siraitia grosvenorii chewable tablets and preparation method thereof | |
| CN103961614B (en) | Chinese medicine composition for treating respiratory disease and its production and use | |
| CN103977315B (en) | Medicinal composition for treating cough with wind-heat affecting lung and preparation method thereof | |
| CN100415209C (en) | Cough stopping preparation and process for preparing the same | |
| KR20170089229A (en) | Composition of Oral Disintegration Film Formulation Containing Ginseng Products And Precess For Producing the Same | |
| CN106913627A (en) | A kind of blue anti-inflammatory syrup in children Pu ground and preparation method thereof | |
| CN1939421A (en) | Antibacterial and antiviral Chinese medicinal composition | |
| CN106361689A (en) | Fudosteine oral solution and preparation method thereof | |
| CN114558049B (en) | Traditional Chinese medicine prescription for treating chronic obstructive pulmonary disease in stationary phase series and application thereof | |
| CN102764294A (en) | Cough relieving and sputum eliminating combination and preparation method thereof | |
| CN105726920A (en) | Anti-PM2.5 chewable tablets and preparing method thereof | |
| CN102657778B (en) | Honeysuckle throat clearing tablets and preparation method thereof | |
| CN107373484B (en) | Cranberry composition with anti-inflammatory effect and preparation method and application thereof | |
| CN102973657B (en) | Cough-relieving Qinbaohong mixture and preparation method thereof | |
| CN102335345B (en) | Chinese medicinal composition for nourishing yin, clearing heat, and moistening lung for arresting cough, and its preparation method | |
| CN102485263B (en) | Medicinal composition for treating chronic cough of children and its preparation method | |
| CN106620351A (en) | Traditional Chinese medicine combination for treating and preventing flu and preparation method thereof | |
| CN103893240A (en) | Composition for preventing and/or treating respiratory system diseases caused by hazes | |
| CN107029092A (en) | A kind of mare's milk sugar-reduction traditional Chinese medicine composition and its preparation method and application |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |